Abstract

The recent increase in the number of X-ray crystal structures of G-protein coupled receptors (GPCRs) has been enabling for structure-based drug design (SBDD) efforts. These structures have revealed that GPCRs are highly dynamic macromolecules whose function is dependent on their intrinsic flexibility. Unfortunately, the use of static structures to understand ligand binding can potentially be misleading, especially in systems with an inherently high degree of conformational flexibility. Here, we show that docking a set of dopamine D3 receptor compounds into the existing eticlopride-bound dopamine D3 receptor (D3R) X-ray crystal structure resulted in poses that were not consistent with results obtained from site-directed mutagenesis experiments. We overcame the limitations of static docking by using large-scale high-throughput molecular dynamics (MD) simulations and Markov state models (MSMs) to determine an alternative pose consistent with the mutation data. The new pose maintains critical interactions observed in the D3R/eticlopride X-ray crystal structure and suggests that a cryptic pocket forms due to the shift of a highly conserved residue, F6.52. Our study highlights the importance of GPCR dynamics to understand ligand binding and provides new opportunities for drug discovery.

Highlights

  • The recent increase in the number of X-ray crystal structures of G-protein coupled receptors (GPCRs) has been enabling for structure-based drug design (SBDD) efforts

  • Compound 1 binds by opening a cryptic pocket, which can be exploited in the design of D3 receptor (D3R) antagonists and, by extension, other aminergic GPCR ligands

  • These structures have been of tremendous importance in drug design[34], with some of these efforts leading to drugs currently in clinical trials

Read more

Summary

Introduction

The recent increase in the number of X-ray crystal structures of G-protein coupled receptors (GPCRs) has been enabling for structure-based drug design (SBDD) efforts. These structures have revealed that GPCRs are highly dynamic macromolecules whose function is dependent on their intrinsic flexibility. GPCRs recognize a wide range of extracellular signals and transduce them into diverse cellular responses Blocking or altering these signals provides extraordinary pharmacological opportunities; not surprisingly, ~34% of marketed drugs target GPCRs1. Up to 25% of the currently marketed drugs bind to aminergic receptors, and eleven distinct ligand-bound active and inactive crystal structures have been published[7]. Most of the D3R antagonist structures disclosed to date share a common 4-feature pharmacophore (A1-B-L-A2), where an aromatic www.nature.com/scientificreports/

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call